{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057256","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.962189+00:00","generated_at":"2026-06-15T13:34:13.643075+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Quoin Pharma Q1 net loss $2.6M; cash $17M; first patient dosed in Netherton trial","bullets":["Net loss $2.6M for Q1 2023 vs $1.7M in Q1 2022; cash & equivalents $17.0M as of March 31, 2023.","First patient dosed in open-label trial of QRX003 for Netherton Syndrome patients on off-label systemic therapy.","Recruiting and dosing continue in double-blinded, placebo-controlled study of QRX003 for Netherton Syndrome.","Completed public offering in Feb 2023 with net proceeds ~$5.8M, extending cash runway into 2H 2024.","Two rare disease programs with Queensland University of Technology; expect clinical testing in Australia in 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057256","json":"https://secwatch.observer/filing/0001104659-23-057256.json","markdown":"https://secwatch.observer/filing/0001104659-23-057256.md","text":"https://secwatch.observer/filing/0001104659-23-057256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923057256/0001104659-23-057256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923057256/tm2314978d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:34:13.643075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4dfd47aafce42baaf2f8db102d02437cb5bfea3c","claim":"Quoin Pharmaceuticals, Ltd. reported the first quarter of 2023 results: net income approximately $2.6 million.","evidence_excerpt":"Net loss for the quarter ended March 31, 2023 was approximately $2.6 million compared to approximately $1.7 million for the quarter ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923057256/0001104659-23-057256-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Net income","value":"approximately $2.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}